{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:00:31Z","timestamp":1792857631366,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Meizhou Science and Technology Plan Project","award":["2022C0301028"],"award-info":[{"award-number":["2022C0301028"]}]},{"name":"Meizhou Science and Technology Plan Project","award":["2022C0301028"],"award-info":[{"award-number":["2022C0301028"]}]},{"name":"Meizhou Science and Technology Plan Project","award":["2022C0301028"],"award-info":[{"award-number":["2022C0301028"]}]},{"name":"Meizhou Science and Technology Plan Project","award":["2022C0301028"],"award-info":[{"award-number":["2022C0301028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03897-w","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:29:16Z","timestamp":1750397356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical efficacy of different neoadjuvant therapies for resectable esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiaoyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danxia","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"6","key":"3897_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"Cancer J Clin"},{"issue":"2","key":"3897_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"Cancer J Clin"},{"issue":"8","key":"3897_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","volume":"156","author":"H Yang","year":"2021","unstructured":"Yang H, Liu H, Chen Y, et al. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial. JAMA Surg. 2021;156(8):721\u20139.","journal-title":"JAMA Surg"},{"issue":"9","key":"3897_CR4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090\u20138.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3897_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68\u201374.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"3897_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","volume":"34","author":"H Tang","year":"2023","unstructured":"Tang H, Wang H, Fang Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Annals oncology: official J Eur Soc Med Oncol. 2023;34(2):163\u201372.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"28","key":"3897_CR7","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1200\/JCO.22.02279","volume":"41","author":"M Faron","year":"2023","unstructured":"Faron M, Cheugoua-Zanetsie M, Tierney J, et al. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. J Clin oncology: official J Am Soc Clin Oncol. 2023;41(28):4535\u201347.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"10447","key":"3897_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet (London England). 2024;404(10447):55\u201366.","journal-title":"Lancet (London England)"},{"issue":"11","key":"3897_CR9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3748\/wjg.v30.i11.1621","volume":"30","author":"A Csontos","year":"2024","unstructured":"Csontos A, Fazekas A, Szak\u00f3 L, et al. Effects of neoadjuvant chemotherapy vs chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis. World J Gastroenterol. 2024;30(11):1621\u201335.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3897_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17(1):54.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3897_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJMc2406031","volume":"391","author":"NH Chakiryan","year":"2024","unstructured":"Chakiryan NH, Strother MC. Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med. 2024;391(2):185\u20136.","journal-title":"N Engl J Med"},{"issue":"1","key":"3897_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41392-023-01636-9","volume":"8","author":"Y Que","year":"2023","unstructured":"Que Y, Wang J, Sun F, et al. Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study. Signal Transduct Target therapy. 2023;8(1):392.","journal-title":"Signal Transduct Target therapy"},{"issue":"12","key":"3897_CR13","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","volume":"27","author":"T van den Ende","year":"2021","unstructured":"van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clin cancer research: official J Am Association Cancer Res. 2021;27(12):3351\u20139.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"3897_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","volume":"144","author":"C Li","year":"2021","unstructured":"Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J cancer (Oxford England: 1990). 2021;144:232\u201341.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"1","key":"3897_CR15","doi-asserted-by":"publisher","first-page":"16495","DOI":"10.1038\/s41598-024-67419-6","volume":"14","author":"Y Kong","year":"2024","unstructured":"Kong Y, Su M, Fang J, et al. Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy. Sci Rep. 2024;14(1):16495.","journal-title":"Sci Rep"},{"key":"3897_CR16","doi-asserted-by":"publisher","first-page":"1108213","DOI":"10.3389\/fimmu.2023.1108213","volume":"14","author":"H Qin","year":"2023","unstructured":"Qin H, Liu F, Zhang Y, et al. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis. Front Immunol. 2023;14:1108213.","journal-title":"Front Immunol"},{"issue":"1","key":"3897_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3892\/mco.2023.2702","volume":"20","author":"H Zeng","year":"2024","unstructured":"Zeng H, Zhang F, Sun Y, Li S, Zhang W. Treatment options for neoadjuvant strategies of esophageal squamous cell carcinoma (Review). Mol Clin Oncol. 2024;20(1):4.","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"3897_CR18","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1245\/s10434-023-14581-2","volume":"31","author":"HB Sun","year":"2024","unstructured":"Sun HB, Yan S, Liu XB, et al. Neoadjuvant Chemotherapy or Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2024;31(4):2443\u201350.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3897_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"key":"3897_CR20","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics. 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021;71(3):209\u2013249.","DOI":"10.3322\/caac.21660"},{"issue":"4","key":"3897_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3322\/caac.21399","volume":"67","author":"TW Rice","year":"2017","unstructured":"Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Cancer J Clin. 2017;67(4):304\u201317.","journal-title":"Cancer J Clin"},{"issue":"2","key":"3897_CR22","first-page":"137","volume":"19","author":"YX Jiang","year":"2015","unstructured":"Jiang YX, Zhang DW, Chen Y, Sun HH, Xu SC, Gao HJ. The characteristics of oesophageal squamous cell carcinoma: an analysis of 1317 cases in southeastern China. Contemp Oncol (Poznan Poland). 2015;19(2):137\u201341.","journal-title":"Contemp Oncol (Poznan Poland)"},{"issue":"8","key":"3897_CR23","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/bjc.2014.101","volume":"110","author":"H Tan","year":"2014","unstructured":"Tan H, Zhang H, Xie J, et al. A novel staging model to classify oesophageal squamous cell carcinoma patients in China. Br J Cancer. 2014;110(8):2109\u201315.","journal-title":"Br J Cancer"},{"issue":"10447","key":"3897_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0140-6736(24)01084-5","volume":"404","author":"SE Al-Batran","year":"2024","unstructured":"Al-Batran SE, Koch C. Neoadjuvant therapy for oesophageal cancer: refining the armamentarium. Lancet (London England). 2024;404(10447):5\u20137.","journal-title":"Lancet (London England)"},{"issue":"1","key":"3897_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-024-02006-x","volume":"23","author":"P Yue","year":"2024","unstructured":"Yue P, Bie F, Zhu J, et al. Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma. Mol Cancer. 2024;23(1):96.","journal-title":"Mol Cancer"},{"key":"3897_CR26","doi-asserted-by":"crossref","unstructured":"Loughney L, Bolger J, Tully R et al. The effect of a pre- and post- operative exercise program versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (The PERIOP-OG Trial): a randomized controlled trial. Int J Surg (London England). 2024.","DOI":"10.1097\/JS9.0000000000001663"},{"issue":"27","key":"3897_CR27","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang H, Liu H, Chen Y, et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin oncology: official J Am Soc Clin Oncol. 2018;36(27):2796\u2013803.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"5","key":"3897_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jamasurg.2021.0133","volume":"156","author":"H Wang","year":"2021","unstructured":"Wang H, Tang H, Fang Y, et al. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA Surg. 2021;156(5):444\u201351.","journal-title":"JAMA Surg"},{"issue":"1","key":"3897_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s12885-017-3446-7","volume":"17","author":"H Tang","year":"2017","unstructured":"Tang H, Tan L, Shen Y, et al. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT(3-4a)N(0\u20131)M(0)) (NCT03001596). BMC Cancer. 2017;17(1):450.","journal-title":"BMC Cancer"},{"issue":"2","key":"3897_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G, et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair\/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin oncology: official J Am Soc Clin Oncol. 2023;41(2):255\u201365.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"35","key":"3897_CR31","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1200\/JCO.23.00170","volume":"41","author":"M Moehler","year":"2023","unstructured":"Moehler M, Xiao H, Blum SI, et al. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric\/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin oncology: official J Am Soc Clin Oncol. 2023;41(35):5388\u201399.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"35","key":"3897_CR32","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin oncology: official J Am Soc Clin Oncol. 2020;38(35):4138\u201348.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"11","key":"3897_CR33","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506\u201317.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3897_CR34","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832\u201342.","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03897-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03897-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03897-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:03:43Z","timestamp":1750442623000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03897-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3897"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03897-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Meizhou People\u2019s\u2019 Hospital (Approve No: 2024-C-68). Informed consent was waived due to the retrospective nature of the study and the use of de-identified patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}